pipeline-prospector-insert
X

Find Immunology Clinical Drug Pipeline Developments & Deals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sutimlimab

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            Sutimlimab, an investigational monoclonal antibody, targets the underlying cause of hemolysis in CAD by selectively inhibiting complement C1s. If approved, sutimlimab would be the first and only approved treatment for these patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NK cell Engager Therapies

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: Undisclosed Upfront Cash: $55.0 million

            Deal Type: Licensing Agreement July 06, 2020

            Details:

            Under the agreement, Dragonfly will grant Bristol Myers Squibb the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary platform for multiple new targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Morphic Therapeutic

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 06, 2020

            Details:

            Under the terms of the extended agreement, HitGen will use its platform technology, based on the design, synthesis and interrogation by selection of DELs to discover ligands for targets of interest to Morphic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ANX005

            Therapeutic Area: Immunology Product Name: ANX005

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Redmile Group

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Financing July 01, 2020

            Details:

            This financing is intended to advance multiple product candidates in Annexon’s portfolio, including ANX005 and ANX007.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CIT-013

            Therapeutic Area: Immunology Product Name: CIT-013

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: BOM Brabant Ventures

            Deal Size: $21.0 million Upfront Cash: Undisclosed

            Deal Type: Financing July 01, 2020

            Details:

            The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Neihulizumab

            Therapeutic Area: Immunology Product Name: AbGn-168H

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            The results of this single dose study showed that Neihulizumab has an acceptable PK and safety profile in patients with SR-aGVHD involving the skin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMVT-1401

            Therapeutic Area: Immunology Product Name: IMVT-1401

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            Based on compelling proof-of-biology for anti-FcRn agents in Myasthenia Gravis (MG), Immunovant has begun preparations to initiate a Phase 3 registrational trial of IMVT-1401 in MG.